UTMD Stock Price, Utah Medical Products Quote, Chart

Market Summary

USD69.72-0.73

Delayed

-1.04%

UTMD Stock Price

View Fullscreen

UTMD RSI Chart

UTMD Valuation

Market Cap

246.0M

Price/Earnings (Trailing)

15.02

Price/Sales (Trailing)

5.02

EV/EBITDA

7.46

Price/Free Cashflow

12.29

UTMD Price/Sales (Trailing)

UTMD Profitability

EBT Margin

40.31%

Return on Equity

12.82%

Return on Assets

12.09%

Free Cashflow Yield

8.14%

UTMD Fundamentals

UTMD Revenue

Revenue (TTM)

49.0M

Rev. Growth (Yr)

-9.42%

Rev. Growth (Qtr)

-8.05%

UTMD Earnings

Earnings (TTM)

16.4M

Earnings Growth (Yr)

-6.12%

Earnings Growth (Qtr)

-7.72%

Breaking Down UTMD Revenue

Last 7 days

1.4%

Last 30 days

3.1%

Last 90 days

-3.7%

Trailing 12 Months

-25.6%

How does UTMD drawdown profile look like?

UTMD Financial Health

Current Ratio

19.57

UTMD Investor Care

Buy Backs (1Y)

2.75%

Diluted EPS (TTM)

4.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	49.0M	0	0	0
2023	52.5M	51.9M	51.5M	50.2M
2022	50.4M	51.2M	51.6M	52.3M
2021	42.2M	46.1M	48.1M	49.1M
2020	47.1M	44.0M	42.0M	42.2M
2019	41.8M	42.7M	44.8M	46.9M
2018	42.0M	42.2M	42.4M	42.0M
2017	39.3M	39.6M	40.1M	41.4M
2016	40.2M	40.3M	40.0M	39.3M
2015	41.7M	41.6M	40.8M	40.2M
2014	39.9M	40.4M	41.1M	41.3M
2013	40.7M	40.7M	40.2M	40.5M
2012	42.3M	41.9M	41.6M	41.6M
2011	25.5M	29.6M	34.2M	37.9M
2010	0	25.7M	25.4M	25.1M
2009	0	0	0	25.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Utah Medical Products Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 15, 2023	koopman brian	gifted	-5,658	94.31	-60.00	principal financial officer
May 18, 2023	richins paul o	sold	-65,429	93.47	-700	-
Mar 17, 2023	richins paul o	gifted	-13,875	92.5	-150	-
Feb 08, 2023	payne barbara a	gifted	-44,998	89.9974	-500	-
Dec 06, 2022	koopman brian	acquired	37,320	74.64	500	principal financial officer
Dec 06, 2022	koopman brian	sold (taxes)	-37,288	101	-366	principal financial officer
Nov 18, 2022	richins paul o	sold	-40,773	90.81	-449	-
Nov 17, 2022	richins paul o	sold	-14,490	90.00	-161	-
Nov 11, 2022	richins paul o	sold	-3,700	92.5	-40.00	-
Oct 31, 2022	koopman brian	gifted	-5,781	88.94	-65.00	principal financial officer

Which funds bought or sold UTMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Ancora Advisors LLC	sold off	-100	-1,402,850	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.94	-23,051	24,533	-%
May 16, 2024	COMERICA BANK	reduced	-20.61	-3,636	7,395	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	256,921	256,921	-%
May 15, 2024	Engineers Gate Manager LP	new	-	276,476	276,476	0.01%
May 15, 2024	CITADEL ADVISORS LLC	added	449	2,188,220	2,788,790	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	260	776,282	1,155,610	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-77.69	-2,359,050	547,547	-%
May 15, 2024	Royal Bank of Canada	reduced	-46.66	-112,000	90,000	-%
May 15, 2024	BRANDES INVESTMENT PARTNERS, LP	added	113	2,220,080	4,984,600	0.06%

Are Funds Buying or Selling UTMD?

Are funds buying UTMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UTMD

No. of Funds

Unveiling Utah Medical Products Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	7.4%	269,166	SC 13G/A
Feb 13, 2024	renaissance technologies llc	5.64%	204,614	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.6%	204,421	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	9.4%	341,916	SC 13G
Feb 13, 2023	renaissance technologies llc	5.81%	210,614	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	4.62%	167,690	SC 13G/A
Feb 01, 2023	blackrock inc.	5.7%	205,514	SC 13G/A
Jun 10, 2022	price t rowe associates inc /md/	10.0%	365,212	SC 13G/A

Recent SEC filings of Utah Medical Products Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 25, 2024	8-K	Current Report
Apr 15, 2024	DEFA14A	DEFA14A
Apr 10, 2024	DEF 14A	DEF 14A
Mar 26, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Utah Medical Products Inc News

Latest updates

Utah Medical Products Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-8.1%	11.00	12.00	13.00	13.00	13.00	14.00	13.00	13.00	12.00	13.00	13.00	13.00	11.00	12.00	10.00	9.00	11.00	12.00	12.00	12.00	11.00
Gross Profit	-4.7%	7.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	6.00	5.00	7.00	8.00	7.00	8.00	7.00
Operating Expenses	-	3.00	-	3.00	3.00	3.00	-	3.00	3.00	3.00	-	3.00	3.00	3.00	-	3.00	3.00	3.00	-	3.00	3.00	3.00
S&GA Expenses	132.7%	3.00	-8.01	3.00	3.00	3.00	-7.27	3.00	3.00	3.00	-7.25	3.00	3.00	3.00	-6.93	3.00	3.00	3.00	-6.60	3.00	3.00	3.00
R&D Expenses	82.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA Margin	0.8%	0.42*	0.41*	0.41*	0.42*	0.42*	0.41*	0.41*	0.40*	0.40*	0.40*	0.39*	0.38*	0.34*	0.35*	-	-	-	-	-	-	-
Income Taxes	15.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00
Earnings Before Taxes	-4.4%	5.00	5.00	5.00	5.00	5.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	2.00	4.00	5.00	4.00	5.00	4.00
EBT Margin	0.8%	0.40*	0.40*	0.40*	0.41*	0.40*	0.40*	0.39*	0.39*	0.39*	0.39*	0.38*	0.36*	0.33*	0.33*	-	-	-	-	-	-	-
Net Income	-7.7%	4.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	3.00	4.00	4.00	4.00	3.00
Net Income Margin	0.8%	0.33*	0.33*	0.33*	0.33*	0.33*	0.32*	0.31*	0.31*	0.30*	0.30*	0.29*	0.28*	0.25*	0.26*	-	-	-	-	-	-	-
Free Cashflow	0.2%	5.00	5.00	5.00	5.00	7.00	6.00	5.00	5.00	5.00	5.00	6.00	4.00	6.00	6.00	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.0%	135	135	131	130	128	124	118	116	120	116	120	117	114	112	107	104	103	110	104	103	105
Current Assets	0.8%	107	106	102	99.00	95.00	90.00	84.00	79.00	79.00	73.00	76.00	71.00	67.00	62.00	57.00	53.00	51.00	55.00	50.00	46.00	46.00
Cash Equivalents	1.0%	94.00	93.00	88.00	85.00	81.00	75.00	70.00	66.00	66.00	61.00	64.00	60.00	56.00	52.00	46.00	42.00	40.00	43.00	37.00	33.00	33.00
Inventory	-3.6%	9.00	10.00	10.00	10.00	10.00	9.00	8.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	6.00	8.00	8.00
Net PPE	-2.7%	10.00	11.00	10.00	11.00	10.00	10.00	10.00	10.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	10.00	10.00	11.00	10.00	10.00	10.00
Goodwill	-0.4%	14.00	14.00	13.00	14.00	14.00	13.00	13.00	13.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	13.00	14.00	14.00
Liabilities	7.8%	8.00	7.00	8.00	9.00	10.00	10.00	10.00	9.00	11.00	8.00	10.00	9.00	10.00	9.00	9.00	8.00	9.00	9.00	9.00	9.00	13.00
Current Liabilities	16.2%	5.00	5.00	4.00	5.00	6.00	6.00	6.00	4.00	6.00	4.00	5.00	4.00	5.00	4.00	4.00	3.00	4.00	3.00	4.00	4.00	7.00
Shareholder's Equity	-0.4%	128	128	124	122	118	114	108	107	109	107	110	107	105	103	98.00	95.00	94.00	101	95.00	94.00	92.00
Retained Earnings	0.5%	139	138	135	132	129	126	123	119	118	115	118	115	113	111	109	107	107	111	107	105	102
Additional Paid-In Capital	-100.0%	-	1.00	1.00	0.00	0.00	0.00	0.00	-	1.00	1.00	1.00	0.00	0.00	0.00	-	0.00	-	0.00	-	-	0.00
Shares Outstanding	-1.1%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-
Float	-	-	-	-	313	-	-	-	336	-	-	-	286	-	-	-	298	-	-	-	327	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1.1%	5,276	5,332	5,121	4,913	6,915	5,680	5,589	4,832	5,046	4,987	5,991	4,692	5,533	5,778	5,008	3,677	5,674	5,641	6,372	1,683	3,360
Share Based Compensation	9.7%	79.00	72.00	53.00	50.00	50.00	62.00	38.00	40.00	43.00	43.00	41.00	41.00	41.00	39.00	49.00	49.00	23.00	28.00	29.00	28.00	28.00
Cashflow From Investing	105.6%	5.00	-90.00	-186	-320	-43.00	-38.00	-321	-222	-237	-253	-77.00	-212	-10.00	-54.00	-95.00	-257	-454	-288	-122	-118	-21,012
Cashflow From Financing	-271.9%	-3,983	-1,071	-1,035	-1,010	-1,049	-920	-1,032	-3,551	19.00	-8,070	-850	-1,036	-949	-942	-1,368	-1,004	-7,420	-969	-976	-1,352	-930
Dividend Payments	1.7%	1,089	1,071	1,071	1,070	1,070	1,051	1,052	1,060	-	8,349	1,039	1,039	1,038	1,019	1,020	1,035	1,042	1,029	1,028	1,028	1,027
Buy Backs	-Infinity%	-2,990	-	-	-	-	-	-	-2,495	-	-	-	-	-	6,976	-551	-	-6,426	398	-	-398	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

UTMD Income Statement

2024-03-31

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME
Sales, net	$ 11,340	$ 12,520
Cost of goods sold	4,574	4,677
Gross profit	6,766	7,843
Operating expense
Selling, general and administrative	2,617	3,260
Research & development	266	144
Total operating expenses	2,883	3,404
Operating income	3,883	4,439
Other income	915	680
Income before provision for income taxes	4,798	5,119
Provision for income taxes	842	905
Net income	$ 3,956	$ 4,214
Earnings per common share (basic)	$ 1.09	$ 1.16
Earnings per common share (diluted)	$ 1.09	$ 1.16
Shares outstanding (basic)	3,618	3,628
Shares outstanding (diluted)	3,618	3,636
Other comprehensive income (loss)
Foreign currency translation net of taxes of $0 in all periods	$ (631)	$ 549
Total comprehensive income	$ 3,325	$ 4,763

UTMD Balance Sheet

2024-03-31

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash & Investments	$ 93,808	$ 92,868
Accounts & other receivables, net	3,591	3,391
Inventories	9,240	9,582
Other current assets	510	428
Total current assets	107,149	106,269
Property and equipment, net	10,266	10,551
Goodwill	13,638	13,692
Other intangible assets	54,029	54,296
Other intangible assets - accumulated amortization	(49,641)	(49,350)
Other intangible assets, net	4,388	4,946
Total assets	135,441	135,458
Current liabilities
Accounts payable	998	769
Accrued expenses	4,476	3,941
Total current liabilities	5,474	4,710
Deferred tax liability - Femcare IIA	986	1,120
Other long term liabilities	698	698
Long-term lease liability	285	295
Deferred income taxes	256	322
Total liabilities	7,699	7,145
Stockholders' equity
Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2024, 3,588 shares and December 31, 2023, 3,628 shares	36	36
Accumulated other comprehensive loss	(11,289)	(10,658)
Additional paid-in capital	0	594
Retained earnings	138,995	138,341
Total stockholders' equity	127,742	128,313
Total liabilities and stockholders' equity	$ 135,441	$ 135,458

About Utah Medical Products Inc

Utah Medical Products Inc Frequently Asked Questions

What is the ticker symbol for Utah Medical Products Inc? What does UTMD stand for in stocks?

UTMD is the stock ticker symbol of Utah Medical Products Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Utah Medical Products Inc (UTMD)?

As of Fri May 17 2024, market cap of Utah Medical Products Inc is 246 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTMD stock?

You can check UTMD's fair value in chart for subscribers.

What is the fair value of UTMD stock?

You can check UTMD's fair value in chart for subscribers. The fair value of Utah Medical Products Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Utah Medical Products Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Utah Medical Products Inc a good stock to buy?

The fair value guage provides a quick view whether UTMD is over valued or under valued. Whether Utah Medical Products Inc is cheap or expensive depends on the assumptions which impact Utah Medical Products Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTMD.

What is Utah Medical Products Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, UTMD's PE ratio (Price to Earnings) is 15.02 and Price to Sales (PS) ratio is 5.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Utah Medical Products Inc's stock?

In the past 10 years, Utah Medical Products Inc has provided 0.054 (multiply by 100 for percentage) rate of return.